angiotensin II receptor blockers (candesartan), added to angiotensin converting enzyme inhibitors
DISEASE INTERVENTION COMPARISON RESULTS
Lancet. 2003 Sep 6;362(9386):767-71 Randomized Controlled Trial, Multicenter Study
IN heart failure, chronic, systolic The Use of
angiotensin II receptor blockers (candesartan), added to angiotensin converting enzyme inhibitors
As Treatment, Chronic
Is better Than
angiotensin converting enzyme (ACE) inhibitors alone
To reduce, at 3.5 years, cardiac events (cardiac death or hospital admission for heart failure): 38% with sartan added VS 42% with AECI alone